EXACT SCIENCES ($EXAS) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.21 per share, beating estimates of -$0.39 by $0.18. The company also reported revenue of $706,790,000, beating estimates of $702,410,933 by $4,379,067.
You can see Quiver Quantitative's $EXAS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EXACT SCIENCES Insider Trading Activity
EXACT SCIENCES insiders have traded $EXAS stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $EXAS stock by insiders over the last 6 months:
- KEVIN T CONROY (President and CEO) purchased 19,500 shares for an estimated $1,001,325
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EXACT SCIENCES Hedge Fund Activity
We have seen 239 institutional investors add shares of EXACT SCIENCES stock to their portfolio, and 310 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 2,462,165 shares (+74.7%) to their portfolio in Q4 2024, for an estimated $138,349,051
- WELLINGTON MANAGEMENT GROUP LLP removed 2,273,697 shares (-15.9%) from their portfolio in Q4 2024, for an estimated $127,759,034
- ARTISAN PARTNERS LIMITED PARTNERSHIP removed 1,805,023 shares (-47.3%) from their portfolio in Q4 2024, for an estimated $101,424,242
- JPMORGAN CHASE & CO removed 1,762,792 shares (-33.5%) from their portfolio in Q4 2024, for an estimated $99,051,282
- CAPITAL WORLD INVESTORS added 1,696,321 shares (+10.7%) to their portfolio in Q4 2024, for an estimated $95,316,276
- ARMISTICE CAPITAL, LLC added 1,617,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $90,859,230
- MACKENZIE FINANCIAL CORP added 1,513,873 shares (+107.7%) to their portfolio in Q4 2024, for an estimated $85,064,523
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EXACT SCIENCES Government Contracts
We have seen $1,403,951 of award payments to $EXAS over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- GERMLINE GENETIC TESTING FOR SLC: $782,000
- GERMLINE GENETIC TESTING FOR SLC: $202,754
- ONCOTYPE PORTFOLIO OF GENOMIC TESTS TO PROVIDE PATIENT CARE SUPPORT IN ANATOMIC PATHOLOGY: $145,066
- ONCOTYPE GENETIC TESTING SERVICES: $114,305
- CONTINUATION OF TNXB AND CAH-X GENETIC TESTING SERVICES FROM PREVENTION GENETICS LLC:1126164 [24-007233]: $60,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
EXACT SCIENCES Analyst Ratings
Wall Street analysts have issued reports on $EXAS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 03/28/2025
- Evercore ISI issued a "Outperform" rating on 01/02/2025
To track analyst ratings and price targets for EXACT SCIENCES, check out Quiver Quantitative's $EXAS forecast page.
EXACT SCIENCES Price Targets
Multiple analysts have issued price targets for $EXAS recently. We have seen 4 analysts offer price targets for $EXAS in the last 6 months, with a median target of $66.0.
Here are some recent targets:
- Subbu Nambi from Guggenheim set a target price of $60.0 on 03/28/2025
- Vijay Kumar from Evercore ISI set a target price of $70.0 on 01/02/2025
- Catherine Schulte from Robert W. Baird set a target price of $67.0 on 11/06/2024
- Mark Massaro from BTIG set a target price of $65.0 on 11/06/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
